Summary & Overview
HCPCS Level II Q0239: Injection, bamlanivimab-xxxx, 700 mg
HCPCS Level II code Q0239 denotes a 700 mg injection of bamlanivimab-xxxx, a monoclonal antibody preparation used in outpatient intravenous infusion settings. This code matters nationally because monoclonal antibody therapies have been widely used in short-term treatment programs and public health responses, influencing payer coverage policies, site-of-service utilization, and billing workflows across the country.
Key payers referenced in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of how Q0239 is billed and where it is most commonly administered, plus national perspectives on payer coverage patterns. The publication provides benchmarks for service settings, guidance on claim line presentation, and a summary of relevant policy and coding considerations that affect reimbursement and operational planning.
Content is intended for billing managers, revenue cycle staff, and policy analysts seeking a national summary of the code’s use, payer landscape, and clinical context.
Billing Code Overview
HCPCS Level II code Q0239 describes Injection, bamlanivimab-xxxx, 700 mg. This code represents administration of a single 700 mg dose of the monoclonal antibody product bamlanivimab-xxxx for therapeutic use.
-
Service type: Intravenous monoclonal antibody injection
-
Typical site of service: Infusion center, outpatient clinic, or hospital outpatient department
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with early, mild-to-moderate symptomatic SARS-CoV-2 infection who is at high risk for progressing to severe COVID-19. The patient presents to an outpatient infusion center, emergency department observation unit, or hospital-based infusion clinic within 10 days of symptom onset. Before treatment, a clinician documents a positive SARS-CoV-2 test, assesses symptom duration and risk factors (age ≥65, obesity, chronic kidney disease, diabetes, immunosuppression, cardiovascular or chronic lung disease), reviews current medications and allergies, and obtains baseline vital signs and oxygen saturation.
The clinical workflow includes: pre-visit screening for eligibility and contraindications; informed consent discussion; verification of the ordered agent Q0239 (bamlanivimab, 700 mg); preparation of the monoclonal antibody by pharmacy under sterile conditions; patient arrival, verification of identity and consent, and IV placement by nursing; administration of the infusion per local protocol with continuous monitoring for infusion-related reactions for at least one hour post-infusion; documentation of drug lot number, time of start and stop, and any adverse events; and discharge with post-infusion instructions and follow-up. Billing uses HCPCS Level II code Q0239 for the drug; facility and professional services may use separate CPT/HCPCS J-codes or infusion administration codes as appropriate.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|